The global peptide drug conjugates market is on a transformative trajectory, with projections indicating a significant leap in market value to USD 5,331.83 million by 2033. This forecasted growth underscores an impressive Compound Annual Growth Rate (CAGR) of approximately 20% from 2023 to 2033, starting from an initial valuation of USD 861.12 million at the beginning of the period.
Peptide drug conjugates are at the forefront of therapeutic innovation, revolutionizing the way treatments are delivered. By merging peptides with other molecules, such as small molecules or antibodies, PDCs offer a targeted approach that delivers drugs directly to diseased cells or tissues. This precision not only amplifies the therapeutic impact but also minimizes potential side effects on healthy cells, marking a significant advancement in patient care.
The growing attention towards PDCs is driven by the numerous advantages these compounds offer. The ability to attach a peptide to a drug or targeting moiety allows for highly specific targeting of diseased cells or tissues, which enhances the drug’s efficacy while reducing side effects. This targeted approach is paving the way for more precise treatments, ultimately leading to better patient outcomes.
The PDC market’s steady growth is fueled by several key factors, including the rising prevalence of chronic diseases, continuous advancements in peptide synthesis and conjugation technologies, and the increasing demand for personalized medicine. Moreover, the growing interest in biologics and the development of novel peptide-based therapies have further accelerated the market’s expansion.
As the global healthcare landscape continues to evolve, the peptide drug conjugates market is set to play a pivotal role in shaping the future of targeted therapeutics, offering hope for more effective and personalized treatment options for patients worldwide.
Key Takeaways from the Market Study:
- By product, Lutathera segment accounted for the largest share of 80.5% in 2022
- Based on type, therapeutic segment dominated the Peptide Drug Conjugates Industry with the revenue share of 82.3%.
- North America dominated the global market in 2022 with a revenue share of 45.62%.
- Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period.
“Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth,” says an analyst at Future Market Insights.
High Demand for Peptide Drug Conjugates: Uncover the Trends and Insights with Our Detailed Report!
Key Market Players:
Major players are channelling efforts toward expanding their production capacities to strengthen their market share and cater to the growing demand. Market expansion is anticipated to be aided by the growing number of partnerships and collaborations among key players that are looking to increase their presence in the market. Key players in the Peptide Drug Conjugates Industry are:
- Novartis AG
- Oncopeptides AB
- Bicycle Therapeutics
- AstraZeneca
- Cybrexa Therapeutics
- Angiochem Inc.
- Innovasium Soricimed Biopharma
- Theratechnologies
- Coherent Biopharma
- WuXI STA
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for targeted drug therapy.
In December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
More Valuable Insights:
Future Market Insights, in its new offering, presents an unbiased analysis of the global Peptide Drug Conjugates Industry, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Market Segments Covered in the Global Peptide Drug Conjugates Industry:
By Product:
- Lutetium
- Melflufen
- ANG1005
- BT1718
- CBX-12
- Other Pipeline Products
By Type:
- Therapeutic Peptide Drug Conjugates
- Diagnostic Peptide Drug Conjugates
By Region:
- North America Peptide Drug Conjugates Industry
- Latin America Peptide Drug Conjugates Industry
- Europe Peptide Drug Conjugates Industry
- Asia Pacific Peptide Drug Conjugates Industry
- Middle East & Africa Peptide Drug Conjugates Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
